AU2005284244A1 - Stable liquid formulations of plasmid DNA - Google Patents

Stable liquid formulations of plasmid DNA Download PDF

Info

Publication number
AU2005284244A1
AU2005284244A1 AU2005284244A AU2005284244A AU2005284244A1 AU 2005284244 A1 AU2005284244 A1 AU 2005284244A1 AU 2005284244 A AU2005284244 A AU 2005284244A AU 2005284244 A AU2005284244 A AU 2005284244A AU 2005284244 A1 AU2005284244 A1 AU 2005284244A1
Authority
AU
Australia
Prior art keywords
plasmid dna
composition
concentration
dna
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005284244A
Other languages
English (en)
Inventor
Francis Blanche
Michel Couder
David Gaillac
Thierry Guillemin
Nicolas Maestrali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centelion SAS
Original Assignee
Centelion SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Centelion SAS filed Critical Centelion SAS
Publication of AU2005284244A1 publication Critical patent/AU2005284244A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
AU2005284244A 2004-09-17 2005-09-19 Stable liquid formulations of plasmid DNA Abandoned AU2005284244A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
AUPCT/EP2004/011437 2004-09-17
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
AUPCT/EP2005/005213 2005-04-19
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
AU2005284244A1 true AU2005284244A1 (en) 2006-03-23

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005284244A Abandoned AU2005284244A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid DNA

Country Status (14)

Country Link
EP (1) EP1791945A1 (ru)
JP (1) JP2008512997A (ru)
KR (1) KR20070058621A (ru)
CN (1) CN101040041A (ru)
AU (1) AU2005284244A1 (ru)
BR (1) BRPI0515553A (ru)
CA (1) CA2579340A1 (ru)
EA (1) EA011554B1 (ru)
IL (1) IL181753A0 (ru)
MX (1) MX2007003214A (ru)
NO (1) NO20071946L (ru)
NZ (1) NZ553914A (ru)
TN (1) TNSN07087A1 (ru)
WO (1) WO2006029908A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
BR112017014090A2 (pt) * 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
CA3073462A1 (en) * 2017-08-25 2019-02-28 Zoetis Services Llc A method of immobilizing a nucleic acid probe to a solid support
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
JP2021536241A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 核酸を検出する方法
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
KR20230141965A (ko) * 2022-03-24 2023-10-10 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
JP2003516741A (ja) * 1999-12-17 2003-05-20 メルク エンド カムパニー インコーポレーテッド コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン

Also Published As

Publication number Publication date
KR20070058621A (ko) 2007-06-08
CN101040041A (zh) 2007-09-19
MX2007003214A (es) 2007-10-11
IL181753A0 (en) 2007-07-04
EA200700656A1 (ru) 2007-10-26
EA011554B1 (ru) 2009-04-28
WO2006029908A1 (en) 2006-03-23
BRPI0515553A (pt) 2008-07-29
TNSN07087A1 (en) 2008-06-02
NZ553914A (en) 2009-11-27
NO20071946L (no) 2007-05-29
JP2008512997A (ja) 2008-05-01
CA2579340A1 (en) 2006-03-23
EP1791945A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
AU2005233309B2 (en) Method for purifying plasmid DNA
AU2004272748C1 (en) Method of preparation of pharmaceutically grade plasmid DNA
AU2005284244A1 (en) Stable liquid formulations of plasmid DNA
ES2359069T3 (es) Método para purificar adn plásmido.
Prather et al. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification
Prazeres et al. Purification of plasmids for gene therapy and DNA vaccination
EP1737945B1 (en) Method for purifying plasmid dna
Sousa et al. Biomedical application of plasmid DNA in gene therapy: a new challenge for chromatography
ZA200602244B (en) Method of preparation of pharmaceutically grade plasmid DNA
WO2024042236A1 (en) Stable lipid or lipidoid nanoparticle suspensions

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application